semaglutide prediabetes progression to diabetes Weight loss outcomes with based on severity using the individualized metabolic surgery score Semaglutide Approved for Type 2

Colonic L cells from inflamed IL-10-/- mice were found to remain functional

Semaglutide: Tirzepatide is a dual agonist for GLP-1 and GIP receptors

Retatrutide is not yet FDA-approved, but clinical trial data demonstrate a specific dose escalation protocol starting at 2 mg weekly with gradual titration t...

To help navigate this shifting environment, pharma companies should consider the following imperatives: GLP1s are expanding far beyond diabetes and obesity

Manufactured in the USA with global ingredients

Selina Wang reports on Medicares $50 GLP-1 weight-loss drug program, while Heidi Skolnik breaks down long-term benefits, risks and how patients should approach use of the medications.